Abstract: Raloxifene acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. The acid addition salts or solvates thereof are addition salts or solvates of raloxifene and a pharmaceutical acceptable acid selected among succinic acid, lactic acid, malonic acid or sulphuric acid. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation.

Abstract: Raloxifene acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. The acid addition salts or solvates thereof are addition salts or solvates of raloxifene and a pharmaceutical acceptable acid selected among succinic acid, lactic acid, malonic acid or sulphuric acid. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation.

Abstract: Oral pharmaceutical formulation comprising granules having an inert core coated with a layer, comprising a 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazole having anti-ulcer activity, a disintegrant and a surfactant in a matrix of a melt coating substance essentially consisting of one or more esters of glycerol and fatty acids, a separating layer and an enteric coating layer, and a process for the preparation of such formulation using a melt coating technique for the preparation of the benzimidazole containing layer.

Abstract: A rapid release tablet involves as an active ingredient tolfenamic acid or its pharmaceutically acceptable salts having a mean particle size of <10 .mu.m, alginic acid or its pharmaceutically acceptable salts in an amount of 1.5-6.0% by weight, and a superdisintegrant in an amount of at least 6% by weight.

Abstract: The present invention deals with a ranitidine tablet containing at least 30% ranitidine chloride and having a hydroxypropylmethylcellulose containing coating characterized in that the coating comprises hydroxypropylmethylcellulose and ethylcellulose in a mutual ratio between 10:1 and 1:2 as well as a method for producing the desired coating when manufacturing such ranitidine tablets.

Abstract: The present invention relates to hitherto unknown 3-substituted 1,2,3,4-oxatriazole-5-imine compounds which have proved to have biological effects making them suitable for treatment of cardiovascular diseases (blood clots), angina pectoris and asthma, a process for the preparation thereof and a pharmaceutical preparation comprising said compounds.

Abstract: A process for the preparation of 9-substituted quanine derivatives of general formula (I), in which R is C.sub.1 -C.sub.4 -alkyl optionally substituted with one or more hydroxy groups, or R is (.alpha.), benzyl, ribosyl, 2'-deoxyribosyl or (CH.sub.2).sub.n -OR.sup.1 where n is 1 or 2, and R.sup.1 is CH.sub.2 CH.sub.2 OH or (.beta.) or salts thereof, in which a 1-substituted5-(thiocarbamoyl)amino-1H-imidazole-4-carboxamide of general formula (III), where R has the same meaning as in formula (I), is cyclized: a) by treatment with a heavy metal salt of the group of Cu-, Ag-, Pb- and Hg-salts in an aqueous alkaline medium containing at least for equivalents of OH-ions at a temperature form about 0.degree. C. to the reflux temperature, or b) by treatment with a peroxy compound in an aqueous alkaline medium at a temperature of about 0.degree.-30.degree. C., whereafter (I) is isolated by treatment with a acid and, if desired, is converted into a salt.

Abstract: Serum-free growth medium comprising an iron-chelate, aurin-tricarboxylic acid and optionally alkali-metal-EDTA and trace elements together with possible growth factors, wherein the iron-chelate may comprise a mixture of Fe-EDTA and citric acid. The growth medium may be used for quality testing of other growth media, optionally together with a hybridoma cell line from p.sub.3 U.sub.1 tumor cells and B-lymphocytes, which hybridoma also is disclosed.